JP2016534157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534157A5 JP2016534157A5 JP2016550681A JP2016550681A JP2016534157A5 JP 2016534157 A5 JP2016534157 A5 JP 2016534157A5 JP 2016550681 A JP2016550681 A JP 2016550681A JP 2016550681 A JP2016550681 A JP 2016550681A JP 2016534157 A5 JP2016534157 A5 JP 2016534157A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- lymphoma
- use according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 53
- 201000011510 cancer Diseases 0.000 claims 49
- 210000003719 b-lymphocyte Anatomy 0.000 claims 32
- 230000036210 malignancy Effects 0.000 claims 28
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 22
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 20
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 20
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 16
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 12
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 11
- 206010006187 Breast cancer Diseases 0.000 claims 10
- 208000026310 Breast neoplasm Diseases 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 10
- 206010025323 Lymphomas Diseases 0.000 claims 10
- 208000029742 colonic neoplasm Diseases 0.000 claims 10
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 8
- 229960001507 ibrutinib Drugs 0.000 claims 8
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 201000005787 hematologic cancer Diseases 0.000 claims 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 6
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 6
- 201000009777 distal biliary tract carcinoma Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 6
- 201000002528 pancreatic cancer Diseases 0.000 claims 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 6
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 230000002489 hematologic effect Effects 0.000 claims 5
- 229940124291 BTK inhibitor Drugs 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 4
- 201000004085 CLL/SLL Diseases 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 4
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 4
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 4
- 206010070308 Refractory cancer Diseases 0.000 claims 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 4
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000024312 invasive carcinoma Diseases 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 208000037819 metastatic cancer Diseases 0.000 claims 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- -1 CD86 Proteins 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- 101150051188 Adora2a gene Proteins 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 102100038077 CD226 antigen Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102100031351 Galectin-9 Human genes 0.000 claims 2
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 208000002163 Phyllodes Tumor Diseases 0.000 claims 2
- 206010071776 Phyllodes tumour Diseases 0.000 claims 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 206010038111 Recurrent cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 claims 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000005389 breast carcinoma in situ Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 208000022136 colorectal lymphoma Diseases 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 2
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000011059 lobular neoplasia Diseases 0.000 claims 2
- 108091005446 macrophage receptors Proteins 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895988P | 2013-10-25 | 2013-10-25 | |
| US61/895,988 | 2013-10-25 | ||
| US201361899764P | 2013-11-04 | 2013-11-04 | |
| US61/899,764 | 2013-11-04 | ||
| US201361911953P | 2013-12-04 | 2013-12-04 | |
| US61/911,953 | 2013-12-04 | ||
| US201461937392P | 2014-02-07 | 2014-02-07 | |
| US61/937,392 | 2014-02-07 | ||
| US201461968312P | 2014-03-20 | 2014-03-20 | |
| US61/968,312 | 2014-03-20 | ||
| US201462023742P | 2014-07-11 | 2014-07-11 | |
| US201462023705P | 2014-07-11 | 2014-07-11 | |
| US62/023,705 | 2014-07-11 | ||
| US62/023,742 | 2014-07-11 | ||
| PCT/US2014/062278 WO2015061752A1 (en) | 2013-10-25 | 2014-10-24 | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019064721A Division JP2019142890A (ja) | 2013-10-25 | 2019-03-28 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534157A JP2016534157A (ja) | 2016-11-04 |
| JP2016534157A5 true JP2016534157A5 (enExample) | 2017-12-07 |
| JP6508785B2 JP6508785B2 (ja) | 2019-05-08 |
Family
ID=52993668
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550681A Expired - Fee Related JP6508785B2 (ja) | 2013-10-25 | 2014-10-24 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2019064721A Ceased JP2019142890A (ja) | 2013-10-25 | 2019-03-28 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2020210693A Pending JP2021063091A (ja) | 2013-10-25 | 2020-12-18 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019064721A Ceased JP2019142890A (ja) | 2013-10-25 | 2019-03-28 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| JP2020210693A Pending JP2021063091A (ja) | 2013-10-25 | 2020-12-18 | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150118222A1 (enExample) |
| EP (1) | EP3060251A4 (enExample) |
| JP (3) | JP6508785B2 (enExample) |
| KR (1) | KR20160066554A (enExample) |
| CN (1) | CN105848680A (enExample) |
| AU (2) | AU2014339816B2 (enExample) |
| BR (1) | BR112016009200A8 (enExample) |
| CA (1) | CA2927794A1 (enExample) |
| EA (1) | EA201690746A1 (enExample) |
| IL (1) | IL245042A0 (enExample) |
| MX (1) | MX2016005283A (enExample) |
| TW (2) | TWI617309B (enExample) |
| WO (1) | WO2015061752A1 (enExample) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
| MX348422B (es) | 2010-04-22 | 2017-06-12 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| PH12014500122A1 (en) | 2011-07-13 | 2014-03-24 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| BR122022001235B1 (pt) | 2011-11-29 | 2023-04-11 | Ono Pharmaceutical Co., Ltd | Cristal de cloridrato derivado de purinona |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| MA38183A1 (fr) | 2012-11-15 | 2017-03-31 | Pharmacyclics Inc | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase |
| SMT201700160T1 (it) | 2013-04-25 | 2017-05-08 | Beigene Ltd | Composti eterociclici fusi come inibitori di protein chinasi |
| JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
| EP3033079B1 (en) | 2013-08-12 | 2018-10-31 | Pharmacyclics LLC | Methods for the treatment of her2 amplified cancer |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| JP2016531941A (ja) | 2013-09-30 | 2016-10-13 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼの阻害剤 |
| KR102630750B1 (ko) * | 2013-12-17 | 2024-01-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼｃガンマ２及び耐性に関連した変異 |
| ES2806506T3 (es) | 2014-03-25 | 2021-02-17 | Ono Pharmaceutical Co | Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes |
| DK3138555T3 (da) | 2014-04-30 | 2020-12-14 | Fujifilm Corp | Liposomsammensætning og fremgangsmåde til fremstilling heraf |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| WO2016015095A1 (en) * | 2014-07-31 | 2016-02-04 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| EP3193877A4 (en) | 2014-08-07 | 2018-04-04 | Pharmacyclics LLC | Novel formulations of a bruton's tyrosine kinase inhibitor |
| SI3179992T1 (sl) * | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1 |
| TW201618773A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| TW201618772A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物 |
| WO2016128912A1 (en) * | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| JP2018512396A (ja) * | 2015-03-09 | 2018-05-17 | キングス・カレッジ・ロンドン | Ｔｈ１応答を増強するためのｒａｒアルファアゴニストを用いた併用療法 |
| GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
| CN104878104B (zh) * | 2015-06-01 | 2018-05-04 | 北京泱深生物信息技术有限公司 | 胆管癌诊治分子标志物及其应用 |
| CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| US10143699B2 (en) | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| CA2990107A1 (en) * | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| EP3322732A2 (en) | 2015-07-13 | 2018-05-23 | Cytomx Therapeutics Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| WO2017025496A1 (en) * | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
| CN113750238A (zh) | 2015-09-04 | 2021-12-07 | 亚狮康私人有限公司 | 包含瓦尼替尼及抗癌剂之组合疗法 |
| WO2017046746A1 (en) * | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| WO2017058754A1 (en) * | 2015-09-28 | 2017-04-06 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| US20190054090A1 (en) * | 2015-10-01 | 2019-02-21 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| WO2017062354A1 (en) * | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| IL258521B2 (en) * | 2015-10-08 | 2024-01-01 | Macrogenics Inc | Combination therapy for the treatment of cancer |
| WO2017070137A1 (en) * | 2015-10-20 | 2017-04-27 | Bristol-Myers Squibb Company | Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment |
| US10065974B2 (en) * | 2015-10-30 | 2018-09-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| SI3370768T1 (sl) * | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| US10744134B2 (en) | 2015-11-04 | 2020-08-18 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient |
| CN116327902A (zh) * | 2015-11-20 | 2023-06-27 | 纪念斯隆凯特林癌症中心 | 用于治疗癌症的方法和组合物 |
| US11274132B2 (en) * | 2015-12-11 | 2022-03-15 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of PKM2 modulators and HMGB1 |
| PL3402503T3 (pl) * | 2016-01-13 | 2021-04-19 | Acerta Pharma B.V. | Kombinacje terapeutyczne antyfolianu oraz inhibitora btk |
| WO2017129763A1 (en) * | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| KR102845317B1 (ko) | 2016-03-01 | 2025-08-13 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도 |
| JP2019510041A (ja) * | 2016-03-30 | 2019-04-11 | マイクロバイオ カンパニー， リミテッド | 免疫チェックポイントモジュレーターおよび共生微生物叢による発酵産物の併用がん療法 |
| GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
| HRP20240617T1 (hr) | 2016-05-20 | 2024-07-19 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
| WO2017218970A1 (en) * | 2016-06-17 | 2017-12-21 | Varian Medical Systems, Inc. | Immune modulators in combination with radiation treatment |
| EP3474856B1 (en) * | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| WO2018013534A1 (en) * | 2016-07-11 | 2018-01-18 | Dana-Farber Cancer Institute, Inc. | Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents |
| WO2018022831A1 (en) * | 2016-07-28 | 2018-02-01 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
| KR102282794B1 (ko) * | 2016-07-29 | 2021-07-27 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌리논 화합물의 용도 |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| CN109982703A (zh) | 2016-08-25 | 2019-07-05 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂的组合疗法 |
| WO2018039544A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| EP3511016A4 (en) * | 2016-09-06 | 2020-05-20 | Cell-Medicine, Inc. | Immunostimulant |
| WO2018053242A1 (en) | 2016-09-15 | 2018-03-22 | Idera Pharmaceuticals, Inc. | Immune modulation with tlr9 agonists for cancer treatment |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EP4545093A3 (en) * | 2016-11-04 | 2025-08-20 | Aximmune, Inc. | Beta-alethine, immune modulatos, and uses thereof |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| ES2970715T3 (es) | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| GB201701194D0 (en) | 2017-01-24 | 2017-03-08 | Capella Bioscience Ltd | Antigen binding molecules that bind light |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| AU2018265873A1 (en) | 2017-05-12 | 2019-11-28 | Calithera Biosciences, Inc. | Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide |
| CN107099603A (zh) * | 2017-05-31 | 2017-08-29 | 成都克里斯博生物科技有限公司 | 肿瘤免疫t细胞检测试剂盒和检测方法 |
| EP3635410A4 (en) * | 2017-06-04 | 2021-03-10 | Rappaport Family Institute for Research in the Medical Sciences | PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| US11839655B2 (en) * | 2017-09-01 | 2023-12-12 | Microvax, Llc | Combination cancer therapy |
| WO2019070850A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| US12458411B2 (en) | 2017-12-07 | 2025-11-04 | Augmedics Ltd. | Spinous process clamp |
| US11312781B2 (en) | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
| CN108478580A (zh) * | 2018-03-05 | 2018-09-04 | 浙江大学 | 依鲁替尼在制备抗重症肝炎药物中的应用 |
| AU2019237257A1 (en) * | 2018-03-23 | 2020-10-15 | ISR Immune System Regulation Holding AB (publ) | Combinations of macrolide compounds and immune checkpoint inhibitors |
| CN108627641A (zh) * | 2018-04-28 | 2018-10-09 | 璞晞（广州）生物免疫技术有限公司 | 肝病t细胞功能的检测评估方法及试剂盒 |
| US11980507B2 (en) | 2018-05-02 | 2024-05-14 | Augmedics Ltd. | Registration of a fiducial marker for an augmented reality system |
| CN112292117B (zh) * | 2018-06-15 | 2024-06-07 | 詹森药业有限公司 | 包含依鲁替尼的配制品/组合物 |
| JP7364561B2 (ja) * | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| JP2021532116A (ja) * | 2018-07-23 | 2021-11-25 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用 |
| CN110755426B (zh) * | 2018-07-26 | 2022-09-30 | 中国农业大学 | 雷帕霉素及其结构类似物在制备治疗由Msi1基因异位过表达引起疾病的药物中的应用 |
| US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US12421313B2 (en) | 2019-01-25 | 2025-09-23 | Chia Tia Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
| AU2020222359A1 (en) * | 2019-02-15 | 2021-09-02 | Janssen Biotech, Inc. | Combination therapy for treatment of B-cell malignancies |
| MX2021011654A (es) * | 2019-04-03 | 2022-02-21 | Targimmune Therapeutics Ag | Inmunoterapia para el tratamiento del cancer. |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| US20220298225A1 (en) * | 2019-06-03 | 2022-09-22 | The University Of Chicago | Methods and compositions for treating cancer with collagen binding drug carriers |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| US12178666B2 (en) | 2019-07-29 | 2024-12-31 | Augmedics Ltd. | Fiducial marker |
| US11980506B2 (en) | 2019-07-29 | 2024-05-14 | Augmedics Ltd. | Fiducial marker |
| CA3157106A1 (en) * | 2019-11-05 | 2021-05-14 | Scott I. ABRAMS | Combination therapy for cancer |
| US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
| WO2021208963A1 (en) | 2020-04-15 | 2021-10-21 | Beigene, Ltd. | Bcl-2 inhibitor |
| US11389252B2 (en) | 2020-06-15 | 2022-07-19 | Augmedics Ltd. | Rotating marker for image guided surgery |
| TW202216768A (zh) | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Ｌａｉｒ－１結合劑及其使用方法 |
| US20230255948A1 (en) * | 2020-07-31 | 2023-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | Combination Therapy for Cancer |
| US12239385B2 (en) | 2020-09-09 | 2025-03-04 | Augmedics Ltd. | Universal tool adapter |
| WO2022056592A1 (en) * | 2020-09-16 | 2022-03-24 | Olivia Newton-John Cancer Research Institute | Treatment and/or prevention of cancers |
| JPWO2022102715A1 (enExample) * | 2020-11-13 | 2022-05-19 | ||
| CN112516319A (zh) * | 2020-12-08 | 2021-03-19 | 华中农业大学 | 用于治疗乳腺癌的组合药剂 |
| KR102560178B1 (ko) * | 2021-02-10 | 2023-07-27 | 재단법인 대구경북첨단의료산업진흥재단 | 이미다조[1,5-a]피라진 유도체 화합물 및 이를 유효성분으로 함유하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN115068487B (zh) * | 2021-03-11 | 2024-01-30 | 深圳埃格林医药有限公司 | 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 |
| IL308931A (en) * | 2021-06-02 | 2024-01-01 | Beigene Switzerland Gmbh | Methods for treating malignant B cells using a Bcl-2 inhibitor |
| US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
| US12150821B2 (en) | 2021-07-29 | 2024-11-26 | Augmedics Ltd. | Rotating marker and adapter for image-guided surgery |
| WO2023021450A1 (en) | 2021-08-18 | 2023-02-23 | Augmedics Ltd. | Stereoscopic display and digital loupe for augmented-reality near-eye display |
| CN114634564B (zh) * | 2022-04-18 | 2023-04-04 | 北京华驰千盛生物科技有限公司 | 猫用三联卵黄抗体、制剂及制备方法与用途 |
| WO2023203521A1 (en) | 2022-04-21 | 2023-10-26 | Augmedics Ltd. | Systems and methods for medical image visualization |
| CN114886901B (zh) * | 2022-05-16 | 2024-03-22 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 白桦脂酸和rn-18在制备抗猪流行性腹泻病毒药物中的应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| EP4587881A1 (en) | 2022-09-13 | 2025-07-23 | Augmedics Ltd. | Augmented reality eyewear for image-guided medical intervention |
| CN120202004A (zh) | 2022-10-28 | 2025-06-24 | 科赛普特治疗学股份有限公司 | 使用达祖可兰治疗肌萎缩侧索硬化症 |
| WO2024123175A1 (en) * | 2022-12-06 | 2024-06-13 | Erasmus University Medical Center Rotterdam | Compositions for treating immune checkpoint blockade therapy resistant cancers |
| WO2024240025A1 (zh) * | 2023-05-22 | 2024-11-28 | 无锡瓴方生物医药科技有限公司 | 一种联合用药物组合物及其应用 |
| CN119529271B (zh) * | 2024-11-25 | 2025-12-05 | 湖北理工学院 | 一种光敏剂载体及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| EP1302468B1 (en) | 1992-12-29 | 2008-12-17 | Abbott Laboratories | Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| IL126674A (en) | 1996-04-23 | 2005-08-31 | Vertex Pharma | Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives |
| CA2268340A1 (en) | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methods and compositions for immunomodulation |
| ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| EP1964561A1 (en) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
| US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20050250106A1 (en) | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| KR20070083899A (ko) * | 2004-10-01 | 2007-08-24 | 메다렉스, 인코포레이티드 | Ｃｄ30 양성 림프종의 치료 방법 |
| KR101411165B1 (ko) * | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| CN101415409B (zh) * | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| EP2526934B1 (en) * | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| KR101791981B1 (ko) * | 2007-03-14 | 2017-11-01 | 비온실 에스.알.엘. | 화학요법 약물-내성 상피성 종양을 치료하기 위한 ｓｉＲＮＡ-매개 유전자 침묵화 |
| US20100261776A1 (en) * | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| US9371567B2 (en) * | 2010-04-19 | 2016-06-21 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of BTK inhibitors |
| AU2013308595C1 (en) | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| EA201590822A1 (ru) * | 2012-11-02 | 2016-01-29 | Фармасайкликс, Инк. | Адъювантная терапия ингибитором киназы семейства tec |
-
2014
- 2014-10-24 JP JP2016550681A patent/JP6508785B2/ja not_active Expired - Fee Related
- 2014-10-24 KR KR1020167013770A patent/KR20160066554A/ko not_active Withdrawn
- 2014-10-24 WO PCT/US2014/062278 patent/WO2015061752A1/en not_active Ceased
- 2014-10-24 BR BR112016009200A patent/BR112016009200A8/pt not_active Application Discontinuation
- 2014-10-24 TW TW103136913A patent/TWI617309B/zh not_active IP Right Cessation
- 2014-10-24 CN CN201480071331.2A patent/CN105848680A/zh active Pending
- 2014-10-24 CA CA2927794A patent/CA2927794A1/en not_active Abandoned
- 2014-10-24 MX MX2016005283A patent/MX2016005283A/es unknown
- 2014-10-24 EP EP14855030.4A patent/EP3060251A4/en not_active Withdrawn
- 2014-10-24 EA EA201690746A patent/EA201690746A1/ru unknown
- 2014-10-24 US US14/523,782 patent/US20150118222A1/en not_active Abandoned
- 2014-10-24 TW TW106113264A patent/TWI660739B/zh not_active IP Right Cessation
- 2014-10-24 AU AU2014339816A patent/AU2014339816B2/en not_active Expired - Fee Related
-
2016
- 2016-04-11 IL IL245042A patent/IL245042A0/en unknown
-
2019
- 2019-03-28 JP JP2019064721A patent/JP2019142890A/ja not_active Ceased
-
2020
- 2020-01-24 US US16/752,231 patent/US20200397895A1/en not_active Abandoned
- 2020-08-27 AU AU2020223721A patent/AU2020223721A1/en not_active Abandoned
- 2020-12-18 JP JP2020210693A patent/JP2021063091A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534157A5 (enExample) | ||
| Kumar et al. | Chemotherapy and targeted therapy in the management of cervical cancer | |
| JP7470085B2 (ja) | 抗体およびチェックポイント阻害剤の併用療法 | |
| Helissey et al. | The development of immunotherapy in older adults: new treatments, new toxicities? | |
| JP2017506264A5 (enExample) | ||
| MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
| JP2018508512A5 (enExample) | ||
| RU2017133273A (ru) | Ингибиторы pd-1 / pd-l1 для лечения рака | |
| HRP20160212T1 (hr) | Antitijela za terapiju kancera koji eksprimira klaudin 6 | |
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2018508572A5 (enExample) | ||
| JP2014504294A5 (enExample) | ||
| JP2017507990A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2017533266A5 (enExample) | ||
| Jacome et al. | Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab | |
| JP2016520082A5 (enExample) | ||
| JP2016540042A5 (enExample) | ||
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer treatment | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2017014254A5 (enExample) | ||
| JP2020502147A5 (enExample) | ||
| RU2017134148A (ru) | Комбинация тасквинимода или его фармацевтически приемлемой соли и ингибитора pd-1 и/или pd-l1 для применения в качестве лекарственного средства |